Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer

Elizabeth J Folkerd, J Michael Dixon, Lorna Renshaw, Roger P A'Hern, Mitch Dowsett

Research output: Contribution to journalArticlepeer-review

Abstract

To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer. Recent studies have reported that the AI anastrozole has lower effectiveness than tamoxifen in women with high BMI. This effect with high BMI might hypothetically be a result of reduced inhibition of aromatase and suppression of plasma estrogen levels and might be overcome by the use of an increased dose of anastrozole or, alternatively, the use of a more potent AI such as letrozole.
Original languageEnglish
Pages (from-to)2977-80
Number of pages4
JournalJournal of Clinical Oncology
Volume30
Issue number24
DOIs
Publication statusPublished - 20 Aug 2012

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Body Mass Index
  • Breast Neoplasms
  • Estrogens
  • Estrone
  • Female
  • Humans
  • Middle Aged
  • Neoplasms, Hormone-Dependent
  • Nitriles
  • Postmenopause
  • Triazoles

Fingerprint Dive into the research topics of 'Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer'. Together they form a unique fingerprint.

Cite this